Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants with type 1 diabetes~* Body mass index (BMI) between 18.5 and 29.0 kilograms per square meter (kg/m²), inclusive~* Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%)~* Using CSII and stable insulin regimen for at least 6 months prior to inclusion into the trial~* Able to undergo at least 1 hour of moderate-intensity exercise~Exclusion Criteria:~* Are currently participating or recently participated in a clinical trial or any other type of medical research judged to be incompatible with this study~* Have a blood loss of more than 500 milliliters (mL) within the last month~* Have known allergies to insulin lispro, related compounds or any components of the study drug formulation~* Have previously participated or withdrawn from this study~* Have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study~* Participants who have an abnormal blood pressure and/or pulse rate~* Participants with clinically significant cardiac or pulmonary disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence 1: ADBC (Type: EXPERIMENTAL): Period 1: Lyumjev with 50% basal rate reduction (Treatment A)~Period 2: Humalog with 100% basal rate reduction (Treatment D)~Period 3: Lyumjev with 100% basal rate reduction (Treatment B)~Period 4: Humalog with 50% basal rate reduction (Treatment C)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously.
- Treatment Sequence 2: BACD (Type: EXPERIMENTAL): Period 1: Lyumjev with 100% basal rate reduction (Treatment B)~Period 2: Lyumjev with 50% basal rate reduction (Treatment A)~Period 3: Humalog with 50% basal rate reduction (Treatment C)~Period 4: Humalog with 100% basal rate reduction (Treatment D)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously.
- Treatment Sequence 3: CBDA (Type: EXPERIMENTAL): Period 1: Humalog with 50% basal rate reduction (Treatment C)~Period 2: Lyumjev with 100% basal rate reduction (Treatment B)~Period 3: Humalog with 100% basal rate reduction (Treatment D)~Period 4: Lyumjev with 50% basal rate reduction (Treatment A)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously.
- Treatment Sequence 4: DCAB (Type: EXPERIMENTAL): Period 1: Humalog with 100% basal rate reduction (Treatment D)~Period 2: Humalog with 50% basal rate reduction (Treatment C)~Period 3: Lyumjev with 50% basal rate reduction (Treatment A)~Period 4: Lyumjev with 100% basal rate reduction (Treatment B)~Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete